| Literature DB >> 27384157 |
Minhua Li1, Jiangguo Wei1, Xiaofei Yao1, Cheng Wang1.
Abstract
PURPOSE: Primary low-grade thyroid-like papillary adenocarcinomas are extremely rare neoplasms that generally originate in the nasopharynx. Here, we describe a novel case of a 15-year-old Chinese girl who was diagnosed with low-grade thyroid-like papillary adenocarcinoma, including a brief review of the literature to reveal the clinicopathological features of low-grade thyroid-like nasopharyngeal papillary adenocarcinoma.Entities:
Keywords: Human herpesvirus 4; Nasopharynx; Papillary adenocarcinoma; Thyroid gland; Thyroid nuclear factor 1
Mesh:
Substances:
Year: 2016 PMID: 27384157 PMCID: PMC5266392 DOI: 10.4143/crt.2016.195
Source DB: PubMed Journal: Cancer Res Treat ISSN: 1598-2998 Impact factor: 4.679
Clinical summary of reported thyroid-like low-grade nasopharyngeal papillary adenocarcinoma
| No. | Source | Age (yr) | Sex | Location | Size (cm) | Macroscopic appearance | Follow-up | Recurrence |
|---|---|---|---|---|---|---|---|---|
| 1 | Carrizo and Luna [ | 9 | M | Right nasopharyngeal wall | 2.0 | Submucosal mass | 2 yr | N |
| 2 | Carrizo and Luna [ | 13 | M | Roof of the nasopharynx | 1.5 | NA | 15 yr | N |
| 3 | Wu et al. [ | 36 | F | Left nasopharynx | 1 | Pedunculated polypoid mass | 3 yr | N |
| 4 | Fu et al. [ | 68 | M | Roof of the nasopharynx | NA | Pedunculated tumor | 1 yr | N |
| 5 | Bansal et al. [ | 32 | M | Posterior end of the left nasal septum | NA | Pedunculated well-circumscribed lesion | 2 yr | N |
| 6 | Ohe et al. [ | 25 | M | Roof of the pharynx | 0.8 | Pedunculated mass | 13 mo | N |
| 7 | Ohe et al. [ | 41 | M | Posterior roof of the nasopharynx | 0.5 | Pedunculated mass | 9 mo | N |
| 8 | Sillings et al. [ | 19 | M | Posterior superior free edge of the nasal septum | 1.5 | Pedunculated mass | NA | N |
| 9 | Petersson et al. [ | 39 | F | Posterior edge of bony septum | 1 | Polypoid mass | NA | N |
| 10 | Huang et al. [ | 36 | F | Roof of the nasopharynx | NA | Pedunculated tumor | 31 mo | N |
| 11 | Ozer et al. [ | 17 | F | Posterior nasopharyngeal wall | 2.7×2.2 | Bilobulated mass | 1 yr | N |
| 12 | Oishi et al. [ | 47 | F | Posterior edge of the left nasal septum | 2 | Pedunculated mass | 19 mo | N |
| 13 | Ozturk et al. [ | 24 | F | Posterior septum | 3.0×2.5 | Polypoid mass | 4 yr | N |
| 14 | Wu and Liu [ | 31 | M | Posterior of the nasopharynx | 0.6×0.5×0.6 | Polypoid mass | 9 yr and 8 mo | N |
| 15 | Wu and Liu [ | 49 | M | Pharyngeal recess of the nasopharynx | 1.5×1 | NA | 4 yr and 7 mo | N |
| 16 | Wu and Liu [ | 62 | M | Posterior nasal septum | 0.5×0.5×0.3 | NA | 1 yr and 4 mo | N |
| 17 | Wu and Liu [ | 42 | F | Roof of the nasopharynx | 1×1×0.5 | NA | 7 mo | N |
| 18 | Wu and Liu [ | 51 | M | Posterior nasal septum | 1×1×0.8 | Pedunculated papillary mass | 1 mo | N |
| 19 | Zhang et al. [ | 57 | F | Nasopharynx | 2×1.5×1.5 | Papillary mass | 9 mo | N |
| 20 | Kang et al. [ | 25 | M | Nasopharynx | NA | Polypoid mass | 1 yr | N |
| 21 | Kang et al. [ | 36 | M | Posterior nasal septum | 0.8×0.8×0.8 | Polypoid mass | 18 mo | N |
| 22 | Li et al. [ | 26 | F | Roof of the nasopharynx | 1.5×1.3×0.4 | Polypoid mass | 8 mo | N |
| 23 | Han et al. [ | 40 | F | Roof of the right posterior nasopharynx | 2×1 | Pedunculated polypoid mass | 1 yr | N |
| 24 | Chen et al. [ | 42 | F | Roof of the nasopharynx | 0.5×0.5 | Polypoid mass | 1 yr | N |
| 25 | Present case | 15 | F | Posterior nasal septum | 2.5×2 | Pedunculated polypoid mass with smooth surface | 24 mo | N |
M, male; N, no; NA, not acquired; F, female.
Fig. 1.Nasal endoscopy shows a pedunculated polypoid mass originating in the posterior nasal septum.
Summary of primary antibodies and results of immunohistochemistry
| Antibody | Source | Dilution | Result |
|---|---|---|---|
| CK | Ascend Bio, Guangzhou, China | 1:100 | + |
| EMA | Ascend Bio, Guangzhou, China | 1:100 | + |
| Vim | Ascend Bio, Guangzhou, China | 1:100 | + |
| CK7 | Ascend Bio, Guangzhou, China | 1:100 | + |
| CD15 | Ascend Bio, Guangzhou, China | 1:200 | – |
| TTF-1 | Ascend Bio, Guangzhou, China | 1:400 | + |
| Ki-67 | Ascend Bio, Guangzhou, China | 1:200 | 5% in the most concentrated spot |
| P40 | ZSGB Bio, Beijing, China | 1:200 | - |
| S-100 | Dako, Glostrup, Denmark | 1:3,200 | - |
| GFAP | Dako, Glostrup, Denmark | 1:1,600 | - |
| CK20 | Ascend Bio, Guangzhou, China | 1:200 | - |
| CDX2 | Ascend Bio, Guangzhou, China | 1:400 | - |
| Thyroglobulin | Ascend Bio, Guangzhou, China | 1:800 | - |
| EBER | Triplex International Bio, Fuzhou, China | RTU | - |
CK, cytokeratin; EMA, epithelial membrane antigen; Vim, vimentin; TTF-1, thyroid transcription factor-1; GFAP, glial fibrillary acidic protein; CK, cytokeratin; EBER, Epstein-Barr virus–encoded RNA; RTU, ready to use.
Fig. 2.(A) The tumor displayed papillary structures with hyalinized fibrovascular cores (H&E staining, ×100). (B) Most papillae were lined with cuboidal or columnar epithelia (H&E staining, ×200). (C) Overlapping round to ovoid nuclei that displayed fine chromatin and psammoma bodies were exhibited (H&E staining, ×400). (D) Strong positive staining of cytokeratin 7 was displayed (immunohistochemical [IHC] staining, ×200). (E) Nuclear staining for thyroid transcription factor 1 was shown (IHC staining, ×200). (F) Positivity of vimentin was evident (IHC staining, ×200).